Posted by Michael Wonder on 03 Jun 2025
Amylyx Pharmaceuticals receives US FDA fast track designation for AMX0114 for the treatment of amyotrophic lateral sclerosis
3 June 2025 - AMX0114 is an Amylyx developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in amyotrophic lateral sclerosis.
Amylyx Pharmaceuticals today announced that the US FDA has granted fast track designation to AMX0114, an investigational antisense oligonucleotide targeting calpain-2 for the treatment of people living with amyotrophic lateral sclerosis.
